Is Zevra Therapeutics (ZVRA) Pricing Reflect Its Strong DCF Upside Potential? [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
If you are wondering whether Zevra Therapeutics is attractively priced or already reflecting a lot of optimism, you will want to look closely at how its current share price compares with different measures of value. The stock most recently closed at US$8.97, with returns of 4.4% over the past 7 days and 21.9% over the last year, while the 5 year return sits at a 4.9% decline. Recent attention on Zevra has centered on its position in the pharmaceuticals and biotech space and how investors weigh the risks and potential of its pipeline against the current share price. That backdrop helps explain why short term moves, such as the flat 30 day return alongside a 7.6% gain year to date, may be drawing fresh interest from both cautious and optimistic investors. On our valuation checks, Zevra scores a full 6 out of 6 for being assessed as undervalued. You can see the breakdown in our valuation score , which sets up a closer look at standard valuation approaches next and hints at an even
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results CallGlobeNewswire
- Zevra Therapeutics to Present at the Citizens Life Sciences ConferenceGlobeNewswire
- Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesBusiness Wire
- Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposiumâ„¢ [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposiumâ„¢GlobeNewswire
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 2/10/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- ZVRA's page on the SEC website